The biggest deal of the week, Daiichi’s purchase of the California biotech Plexxikon for $805 million upfront, prompted headlines elsewhere ...

It's always fun to read between the lines--and put in a few calls--when CEOs depart over 'strategic differences' with their boar...

The biopharma industry got glamorous this week with the debut of Extraordinary Measures , a ripped-from-the-headlines biopic based on John C...